medicine

Tempus AI Inc. (NASDAQ:TEM), an artificial intelligence-powered precision medicine solutions provider, which was listed on exchanges in June 2024 has seen major funds investing in the company during the fourth quarter of the year. What Happened: Tempus AI provides a two-pronged approach to...

"We got really lucky about six years ago when we started exploring how cannabinoids might be used to treat drug-resistant infections," says Dr. Dana Lambert, CEO of Andira Pharmaceuticals, in an exclusive interview with Benzinga. Dr. Lambert doesn't speak like an academic. Despite holding a Ph.D....

Strategists are formulating counter-messages for Republicans against President Joe Biden‘s plan to negotiate Medicare drug prices, arguing that it could stifle innovation and lead to price controls, Politico reported. The GOP’s reframing of the drug pricing debate comes as Democrats...

This article was originally published on Cannabis & Tech Today and appears here with permission. The cannabis plant has enjoyed a colorful history around the world and is cultivated for a wide range of applications.  Known by a variety of monikers such as hemp and marijuana, cannabis is...

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr. Reddy's Laboratories Ltd (NYSE: RDY) to acquire its exclusive license of E7777, a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from the completed Phase 2 clinical trial of EB613 for osteoporosis. The company states that its EB613 is positioned to be the...

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ: BIIB) stock earlier this month when its Alzheimer's treatment Aduhelm was approved. Details on key catalytic events...

Clover Health Investments Corp (NASDAQ: CLOV) has been chosen by the Centers for Medicare and Medicare Services (CMS) to participate in Direct Contracting (DC) across 10 states. While the news is not surprising, the program’s official launch is positive for the company, according to BofA...

Moderna, Inc. (NASDAQ: MRNA), which shot to prominence with its coronavirus vaccine program, is beefing up its research and development team. What Happened: Jonathan Hoggatt, who was a principal faculty member at Harvard Stem Cell Institute, has joined Cambridge, Massachusetts-based Moderna...

This article was originally published on Microdose Psychedelic Insights and appears here with permission. MagicMed is a Key Player in the Psychedelic Medicine Development Process The current pharmaceutical regulatory process is, to say the least, inherently daunting for most drug...

This article was originally published on The Cannigma, and appears here with permission. Does cannabis use, medicinal or otherwise, have a long-term, negative impact on cognitive function? Years of studies have provided complex and often conflicting answers, particularly when it comes to teenage...

Epidyolex, the first FDA approved CBD medicine for severe epilepsy in children, received Australian Therapeutic Goods Administration approval. GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Wednesday that TGA authorized the medicine to treat Lennox-Gastaut syndrome (LGS) or Dravet...

On Friday, UK-based mental health care company Compass Pathways (NASDAQ: CMPS) announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange. JR Rahn, CEO of psychedelics drug development company Mind...

A Brazilian medical education company is tapping the IPO market this week. The IPO Terms Afya has filed to offer 13.74 million Class A common shares in an IPO, with 11.83 million shares to be sold by the company and the remaining 1.92 million shares by selling shareholders, according to the F-1/A...

For all the talk and, yes, hype about the marijuana industry's so-called “green rush,” the big pharmaceutical companies appeared to be giving cannabis-based treatments the cold shoulder because of federal laws outlawing marijuana. Given the legal, political and cultural inroads...